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2 Polyphenols have great potential in regulating intestinal health and ameliorating 
 
3 pathological conditions related to increased intestinal permeability (IP). 
 
4 However, the efficacy of dietary interventions with these phytochemicals may 
 
5 significantly be influenced by inter-individual variability factors affecting their 
 
6 bioavailability and consequent biological activity. In the present study, urine 
 
7 samples collected from older subjects undergoing a crossover intervention trial 
 
8 with polyphenol-rich foods were subjected to metabolomics analysis for 
 
9 investigating the impact of increased IP on the bioavailability of polyphenols. 
 
10 Interestingly, urinary levels of phase II and microbiota-derived metabolites were 
 
11 significantly different between subjects with healthier intestinal barrier integrity 
 
12 and those with increased IP disruption. Our results support that this IP- 
 
13 dependent impaired bioavailability of polyphenols could be attributed to 
 
14 disturbances in the gut microbial metabolism and phase II methylation 
 
15 processes. Furthermore, we also observed that microbiota-derived metabolites 
 
16 could be largely responsible for the biological activity elicited by dietary 
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27 The intestinal barrier is a complex functional structure that separates the gut 
 
28 luminal environment from the inner host, which is composed of a physical wall 
 
29 comprising epithelial cells and mucus layers, but also other elements such as 
 
30 the gut microbiota, immunological elements (e.g. immunoglobulin A, cytokines), 
 
31 as well as the intestinal endocrine, neuroenteric and vascular systems.1 The 
 
32 integrity of this barrier is crucial in human health for maintaining normal 
 
33 intestinal permeability (IP), which regulates the transport and absorption of 
 
34 nutrients (e.g. sugars, vitamins, amino acids, fatty acids and other lipids) and 
 
35 other food-related compounds (e.g. polyphenols), and the translocation of 
 
36 bacterial components from the lumen to the bloodstream. The IP is controlled 
 
37 by a complex system of junctions, namely tight junctions (TJ), gap junctions and 
 
38 adherens junctions, comprising a myriad of transmembrane proteins (e.g. 
 
39 occludins, claudins) and junctional adhesion molecules that rule the flux 
 
40 between adjacent enterocytes.2 However, the disruption of these intestinal 
 
41 junctions leads to increased IP, a pathological condition also known as leaky 
 
42 gut. This results in the diffusion of toxins, viruses and bacterial fragments from 
 
43 the intestinal environment to the circulating stream, which consequently 
 
44 activates the immune function and provokes systemic inflammation.3 Increased 
 
45 IP has been proposed as a major contributor to multiple diseases, including 
 
46 gastrointestinal (e.g. irritable bowel syndrome, celiac disease),4 metabolic (e.g. 
 
47 obesity, type II diabetes),5 cardiovascular (e.g. atherosclerosis, chronic heart 
 
48 failure),6 psychiatric (e.g. depression, autism)7 and neurodegenerative (e.g. 
 
49 Parkinson’s disease, Alzheimer’s disease) disorders.8 Furthermore, it is also 
 






51 to the characteristic low-grade systemic inflammation detected in older adults, 
 
52 i.e. the inflamm-aging process.9 The most common causes behind this age- 
 
53 related increase of the IP include impairments in the intestinal epithelial and 
 
54 mucus barriers,10 declined immune function (i.e. immune senescence)9 and 
 
55 changes in the gut microbiota composition.11 
 
56 Adequate nutritional status is crucial for maintaining normal gut barrier function. 
 
57 Adherence to the Western diet, characterized by high fat and sugar intake, is 
 
58 associated with increased IP,12,13 whereas the Mediterranean diet, rich in fruits, 
 
59 vegetables and fiber, prevents the leaky gut.13 In this vein, numerous studies 
 
60 have been conducted during the last years aimed to test the efficacy of dietary 
 
61 interventions for improving the IP and related conditions, with special focus on 
 
62 polyphenols.14,15 These bioactive compounds are secondary metabolites widely 
 
63 distributed in plant-derived foods, including fruits, vegetables, legumes, cereals, 
 
64 beverages (e.g. tea, coffee) and many other foods, with recognized antioxidant 
 
65 and anti-inflammatory properties. Thus, it has previously been reported that 
 
66 polyphenols can ameliorate the leaky gut by directly regulating the TJ function, 
 
67 enhancing the synthesis and redistribution of TJ proteins, such as occludin, 
 
68 claudins and zonula occludens,16,17 and by inhibiting different kinases involved 
 
69 in TJ expression.2 Polyphenolic compounds are also able to block the 
 
70 production of inflammatory cytokines (e.g. necrosis factors, interleukins) and 
 
71 oxidative stress, thus protecting the intestinal barrier integrity.2 Furthermore, 
 
72 polyphenols and the gut microbiota are interconnected through a bidirectional 
 
73 network, which plays a pivotal role in the intestinal health.18 On one hand, the 
 
74 gut microbiota is involved in the biotransformation processes needed for the 
 






76 have described that microbiota-derived metabolites could be responsible, at 
 
77 least in part, for the intrinsic biological effects traditionally attributed to 
 
78 polyphenols, especially taking into consideration the usual low bioavailability of 
 
79 the parent compounds.19 Complementarily, the prebiotic activity of polyphenols 
 
80 and microbiota derivatives is also well known,20 being the consumption of 
 
81 polyphenol-rich foods able to shape the microbiota composition towards the 
 
82 preservation of the intestinal barrier health by means of different mechanisms. 
 
83 For instance, the gut microbiota may directly influence the IP by contributing to 
 
84 the intestinal barrier integrity (e.g. affecting the turnover of intestinal epithelial 
 
85 cells, organization of TJs), but it is also involved in the modulation of 
 
86 inflammation.21,22 Accordingly, the dietary-driven manipulation of the intestinal 
 
87 microbial ecosystem with polyphenols has previously demonstrated great 
 
88 efficacy for improving the IP and related inflammatory processes.23-25 However, 
 
89 to the best of our knowledge, there is currently a total lack of studies focused on 
 
90 determining how increased IP and associated pathological conditions occurring 
 
91 during aging, such as inflammation and microbial dysbiosis, may affect the 
 
92 bioavailability of polyphenols, and consequently impact their biological activity. 
 
93 The aim of the present work is to investigate for the first time the impact of 
 
94 increased IP in older subjects on the bioavailability of dietary polyphenols, and 
 
95 therefore on their bioactivity and capacity to modulate the intestinal barrier 
 
96 integrity. To this end, a crossover intervention trial with a polyphenol rich diet 
 
97 was conducted in older adults, and serum zonulin was measured as a marker of 
 
98 the intestinal barrier integrity for stratifying the population in two sub-groups 
 
99 according to their IP (i.e. increased IP dysfunction and healthier subjects). 
 






101 characterize the urinary food-related metabolome, comprising polyphenolic and 
 
102 other food-origin compounds, metabolites derived from phase I/II metabolism, 
 
103 and microbial-transformed derivatives.26,27 
 
104 MATERIALS AND METHODS 
 
105 Study design 
 
106 A randomized, controlled, crossover intervention trial with polyphenol-rich foods 
 
107 was conducted in older people living in a residential care setting (i.e. the MaPLE 
 
108 study, Microbiome mAnipulation through Polyphenols for managing Leakiness 
 
109 in the Elderly), as described elsewhere.28 The study was performed in 
 
110 accordance with the principles contained in the Declaration of Helsinki. The 
 
111 Ethics Committee of the University of Milan approved the study protocol, and all 
 
112 the participants provided written informed consent. The trial was registered 
 
113 under ISRCTN.com (ISRCTN10214981). 
 
114 Briefly, 51 older subjects (≥ 60 y) completed a crossover trial consisting of a 
 
115 polyphenol-rich diet (PR-diet) and a control diet (C-diet), each one of the arms 
 
116 lasting for 8 weeks and being separated by an 8-week wash-out period. Serum 
 
117 zonulin levels were measured as a marker of IP (Immunodiagnostik® ELISA kit, 
 
118 Bensheim, Germany),29 and the median value within the study population 
 
119 (median = 40 ng/mL) was employed to stratify subjects in two sub-groups: the 
 
120 lower serum zonulin at baseline (LSZ) group (serum zonulin at baseline ≤ the 
 
121 median value) and the higher serum zonulin at baseline (HSZ) group (serum 
 
122 zonulin at baseline > the median value). Accordingly, zonulin levels were 33.2 ± 
 
123 5.6 ng/mL and 51.5 ± 8.9 ng/mL (expressed as the mean ± standard deviation) 
 
124 for the LSZ and HSZ individuals, respectively. Subjects in these two groups 
 






126 10.2 y) and BMI (26.4 ± 6.4 vs 27.2 ± 4.5 kg/m2). During the C-diet period, 
 
127 subjects consumed the regular menu provided by the nursing home, whereas 
 
128 the PR-diet was designed by substituting three portions per day of low- 
 
129 polyphenol products from the C-diet with food items with higher polyphenol 
 
130 content, but maintaining comparable levels of energy and nutrients. Specifically, 
 
131 PR-foods employed in this intervention study were berries (raw fruits and 
 
132 puree), blood orange (raw fruits and juice), pomegranate juice, green tea, 
 
133 Renetta apple (raw fruits and puree) and cocoa (chocolate callets and cocoa 
 
134 powder drink). At baseline and after each intervention period, subjects were 
 
135 asked to fast overnight for collecting serum and first morning void urine 
 
136 samples. Detailed description about the inclusion and exclusion criteria, the 
 
137 intervention trial, and the collection of biological samples has been previously 
 
138 reported by Guglielmetti et al.28 
 
139 Metabolomics analysis of urine samples 
 
140 Multi-targeted quantitative metabolomics analysis of the urinary food 
 
141 metabolome was accomplished by ultra-high-performance liquid 
 
142 chromatography coupled to tandem mass spectrometry (UHPLC-MS/MS), 
 
143 following the methodology optimized by González-Domínguez et al.26,27 To this 
 
144 end, urine samples were subjected to solid-phase extraction (SPE) using 
 
145 Oasis® HLB extraction plates (Waters, Milford, MA, USA) with the aim of 
 
146 simultaneously extracting and pre-concentrating polyphenols and other food- 
 
147 related compounds, and their biotransformed metabolites (i.e. phase I/II and 
 
148 microbiota derivatives). Complementarily, urine samples were also analyzed 
 
149 after tenfold dilution to determine highly concentrated metabolites and polar 
 






151 standards (taxifolin and caffeine-13C3, 100 μg/L) was added to all the samples 
 
152 for quantification and quality control (QC) assessment, as previously 
 
153 described.26,27 Subsequent UHPLC-MS/MS metabolomics fingerprinting was 
 
154 performed by using the chromatographic and MS conditions described 
 
155 elsewhere for the simultaneous detection and quantitation of almost 350 dietary 
 
156 compounds and their host and microbial metabolites.26 Metabolomics results 
 
157 were normalized in reference to the urinary refractive index (OPTi Digital 
 
158 Handheld Refractometer, Bellingham+Stanley, UK) to account for inter- 
 
159 individual differences in the hydration status and micturition frequency. 
 
160 Quality control assessment 
 
161 Quality control (QC) assessment of the metabolomics data was carried out by 
 
162 using a standardized protocol developed in-house. For this purpose, data were 
 
163 first pre-processed for removing metabolites with more than 20% missing 
 
164 values in all the study groups.30 The remaining missing values were imputed by 
 
165 using the root square of the limit of detection for each metabolite,26 and data 
 
166 were then log transformed and Pareto scaled. Afterwards, distances to the 
 
167 group centroid were computed based on Euclidean distances to remove outliers 
 
168 from the data matrix. Metabolites known to be influenced by pre-analytical 
 
169 factors (e.g. hippurate) were checked for the absence of abnormal values 
 
170 (±1.5×IQR), which could be indicative of improper handling/storage of urine 
 
171 samples.31 Finally, the coefficient of variation was computed for areas, retention 
 
172 times and peak widths of the internal standards added to samples with the aim 
 
173 of evaluating the analytical reproducibility along the sequence run. 
 






175 Metabolomics data were pre-processed as detailed in the previous section, and 
 
176 were then subjected to statistical analysis by using R 3.6.2 software packages 
 
177 (http://www.r-project.org) to look for altered metabolites because of the 
 
178 intervention trial and to associate these metabolic alterations with changes in 
 
179 the IP. For this purpose, data normality was first checked by inspecting 
 
180 probability plots. Then, a linear mixed model was built to evaluate the impact of 
 
181 the PR-dietary intervention on urinary metabolites compared with the C-diet, 
 
182 taking into account the repeated measures by subject, the period (pre- and 
 
183 post-intervention) and the arm within the crossover design (i.e. first C-diet and 
 
184 then PR-diet, or vice versa). For each arm of the crossover trial, the effect of the 
 
185 intervention was estimated as the difference between the final and baseline 
 
186 metabolite concentrations. Finally, Pearson’s correlations were computed 
 
187 between serum zonulin levels and significant urinary metabolites according to 
 
188 the previous linear model. All these analyses were conducted in the entire study 
 
189 population (i.e. the MaPLE study), as well as separately in participants stratified 
 
190 according to their baseline zonulin levels (i.e. the LSZ and HSZ sub-groups), as 
 
191 reported in section 2.1. All the statistical analyses were adjusted for the age, 
 
192 sex, BMI and the allocation order in the crossover trial as covariates, and were 
 
193 adjusted for multiple comparisons using the Benjamini-Hochberg false 
 
194 discovery rate (FDR). FDR-corrected p-values below 0.05 were considered 
 
195 statistically significant. 
 
196 RESULTS AND DISCUSSION 
 








199 Metabolomics analysis of urine samples was accomplished to investigate the 
 
200 metabolism and bioavailability of polyphenols supplied through a PR-dietary 
 
201 intervention in older adults. For evaluating the impact of increased IP on 
 
202 metabolomics results, serum zonulin was measured as a surrogate marker of 
 
203 the intestinal barrier integrity, because the high rate of incontinence amongst 
 
204 the elderly participants participating in the intervention trial impeded the 
 
205 lactulose-mannitol urinary test to be performed. In this vein, although there is 
 
206 growing debate about the reliability of using zonulin as a marker of IP,32 it has 
 
207 been previously demonstrated a high correlation between serum zonulin and 
 
208 the urinary lactulose/mannitol ratio.33 On this basis, we stratified the study 
 
209 population according to the baseline zonulin levels with the aim of separately 
 
210 assessing the effect of the PR intervention in subjects with healthier intestinal 
 
211 barrier integrity (i.e. the LSZ group) and in those with increased IP dysfunction 
 
212 (i.e. the HSZ group). This is in line with previous works reporting that serum 
 
213 zonulin concentrations are normally raised during aging,34 but especially in older 
 




216 The PR-diet supplied an average of 724 mg of total polyphenols per day, thus 
 
217 almost doubling the estimated polyphenol intake compared with the C-diet.28 
 
218 We observed that this PR-dietary intervention induced a slight decrease of 
 
219 serum zonulin levels in the MaPLE population.36 This finding is supported by 
 
220 numerous scientific evidence that highlight the great potential of polyphenols in 
 
221 regulating the intestinal barrier function and preventing leaky gut, both in vitro 
 
222 and in vivo.2,16 However, different behaviors were interestingly observed when 
 






224 the subjects with higher IP (i.e. HSZ group) experienced a significant decrease 
 
225 of serum zonulin, whereas those with LSZ were unaffected. Overall, these 
 
226 results underline the potential existence of different phenotypic groups in the 
 
227 older subjects characterized by the degree of IP, which significantly influences 
 
228 the efficacy of the PR-dietary intervention. This therefore demonstrates the 
 
229 crucial need of investigating the inter-individual variability in the bioavailability of 
 
230 polyphenols driving these discrepancies. 
 
231 To this end, we employed a multi-targeted metabolomics platform with 
 
232 integrated QC assessment, which provided a comprehensive, accurate and 
 
233 quantitative characterization of the urinary food metabolome based on the 
 
234 simultaneous analysis of around 350 diet-related metabolites, including 
 
235 polyphenols and other food-origin compounds, metabolites derived from the 
 
236 host metabolism (i.e. phase I and II transformation processes), and microbiota 
 
237 derivatives.26,27 Among all the metabolites measured, the intervention with PR- 
 
238 foods in the MaPLE trial induced a significant increase of the urinary levels of 
 
239 numerous food and microbiota-related metabolites compared with the C-diet (ca 
 
240 70), as shown in Table 1. The concentrations within the four study groups (i.e. 
 
241 C-diet baseline, C-diet post-intervention, PR-diet baseline, PR-diet post- 
 
242 intervention) for the metabolites significantly altered because of the PR dietary 
 
243 intervention are listed in Tables S1-S3, for the entire MaPLE population, the 
 
244 LSZ and the HSZ sub-groups, respectively. Many of these metabolites are well 
 
245 known food-intake markers, as defined in the Food Biomarker Ontology,37 thus 
 
246 accurately mirroring the consumption of the specific PR-foods employed in this 
 
247 intervention study. The most remarkable finding was the increased urinary 
 






249 methyl(epi)catechins) and their microbiota derived hydroxyphenyl-valeric acids 
 
250 and hydroxyphenyl-γ-valerolactones, associated with the consumption of 
 
251 procyanidin-rich foods (e.g. tea, berries, apple, cocoa). The intake of tea, cocoa 
 
252 and berries during the PR period was also reflected in the urinary excretion of 
 
253 methylgallic acid derivatives, theobromine and cyanidin 3-glucoside, 
 
254 respectively. The production of urolithins, derived from the microbial 
 
255 transformation of ellagitannins, could be attributed to pomegranate and berries. 
 
256 Furthermore, other numerous non-specific metabolites derived from the 
 
257 microbial metabolism of a wide range of polyphenol classes were also 
 
258 accumulated in urine samples, including phenolic acids (e.g. hydroxybenzoic 
 
259 acids, hydroxycinnamic acids) and enterolignans (e.g. enterolactone). 
 
260 Nonetheless, the most remarkable results were obtained when subjects were 
 
261 stratified according to the baseline zonulin levels. For LSZ individuals, the PR 
 
262 dietary intervention induced similar metabolomics changes to those previously 
 
263 described for the entire MaPLE population (Table 1). However, the number of 
 
264 metabolites that were significantly increased as a consequence of the PR-diet in 
 
265 HSZ subjects was considerably lower with respect to the LSZ group, especially 
 
266 regarding microbiota derivatives. The HSZ group of subjects only showed 
 
267 urinary alterations in the levels of flavan-3-ol phase II metabolites, 
 
268 hydroxycinnamic acids and a few other microbiota compounds compared with 
 
269 the C-diet. Interestingly, the fold of increase after the PR-diet for most of these 
 
270 metabolites was more pronounced in LSZ subjects compared with HSZ ones, 
 
271 except for methyl(epi)catechin derivatives that were excreted in larger amounts 
 
272 in this latter group. All this therefore suggests that the baseline IP status could 
 






274 considering that only subjects with a healthier intestinal integrity were able to 
 
275 properly metabolize them. Particularly, metabolic discrepancies between the 
 
276 LSZ and HSZ groups were mainly observed in microbial metabolites, as shown 
 
277 in Table 1, which could support that alterations in the gut microbiota 
 




280 In this context, the gut microbiota has been proposed as one of the most 
 
281 important factors influencing the bioavailability of polyphenols and, 
 
282 consequently, their bioactivity.19 The microbial metabolism of polyphenols 
 
283 usually comprises an initial hydrolysis step of the conjugated species present in 
 
284 foods to release the corresponding aglycones, which can subsequently be 
 
285 transformed by a range of reactions, including ring fissions, dehydroxylations, 
 
286 decarboxylations, demethylations, reductions, and many others.18,38 While 
 
287 numerous enterobacterial species from the four most abundant phyla can be 
 
288 involved in the deconjugation of polyphenols (i.e. Firmicutes, Bacteroidetes, 
 
289 Actinobacteria and Proteobacteria), only two phyla have been associated with 
 
290 further metabolism of the aglycones (Firmicutes and Actinobacteria), as 
 
291 illustrated in Figure 1. Among them, Clostridium and Eubacterium species from 
 
292 the Firmicutes phylum are essential for the bioavailability of most polyphenols 
 
293 by driving C-ring cleavage reactions, which lead to the production of simpler 
 
294 phenolic acids and other intermediates that may undergo subsequent 
 
295 conversions to generate more complex microbiota derivatives (e.g. 
 
296 hydroxyphenyl-γ-valerolactones, urolithins, enterolignans). In contrast, 
 
297 hydroxycinnamic acids are mainly released in the colon by the action of 
 






299 1).38 Within this complex interplay between the gut microbiota and dietary 
 
300 polyphenols, it should be also noted that aging-related impairments in the 
 
301 intestinal health have closely been associated with significant gut dysbiosis. In 
 
302 general, the microbiota composition in older adults is characterized by an 
 
303 overall decrease of the bacterial diversity and stability, with a shift in the 
 
304 proportion of Bacteroidetes (increased) and Firmicutes (decreased) species,39,40 
 
305 and increased abundance of potentially pathogenic and pro-inflammatory 
 
306 bacteria.40-42 Among the Firmicutes, numerous studies have demonstrated that 
 
307 older subjects with impaired intestinal health have decreased content of 
 
308 Clostridium and Eubacterium species,42-44 which are directly involved in the 
 
309 microbial biotransformations of polyphenols as described above. On the other 
 
310 hand, various authors have recently described that aging has not a significant 
 
311 impact on the Bifidobacterium genus,41,44 refuting earlier studies;45,46 whereas 
 
312 contradictory results have been published regarding the influence of aging in 
 
313 Lactobacillus bacteria.47,48 Therefore, these previous metagenomics findings 
 
314 totally support the metabolomic discrepancies observed in the present study 
 
315 between the LSZ and HSZ groups, since older subjects with increased IP (i.e. 
 
316 HSZ) are expected to have lower Firmicutes diversity, thus negatively affecting 
 
317 the bioavailability of most polyphenols and consequently reducing the urinary 
 
318 excretion of their microbiota derivatives, while showing only a minor impact on 
 
319 the content of hydroxycinnamates produced by Bifidobacterium and 
 
320 Lactobacillus species. 
 
321 On the other hand, increased methylation of dietary (epi)catechins was also 
 
322 observed in the HSZ group, which was paralleled by decreased rate of 
 






324 previously described that the in vitro bioavailability and intestinal absorption of 
 
325 methylated polyphenols is considerably higher than that elicited by the 
 
326 corresponding glucuronide and sulfate species.49 These results could therefore 
 
327 suggest that a shift towards increased methylation is induced in HSZ individuals 
 
328 to partially compensate the impairments in the microbial metabolism of 
 
329 polyphenols described above. This sharpened excretion of phase II 
 
330 methyl(epi)catechin metabolites in the HSZ group could be attributed to altered 
 
331 expression of catechol-O-methyltransferase, the enzyme responsible for the 
 
332 conversion of dietary polyphenols into their methylated analogues.50 The proper 
 
333 regulation of this catechol-metabolizing system has been demonstrated to be 
 
334 crucial in human health due to its potential pathophysiological and pathogenic 
 
335 role in neurodegenerative diseases, cancers and cardiovascular disorders.51 
 
336 However, this is the first time to our knowledge that an IP-dependent regulation 
 
337 of this methylation system is described in older adults. 
 
338 Association between dietary polyphenols, microbial metabolites and 
 
339 intestinal barrier health 
 
340 To further investigate the possible impact of the hypothesized IP-driven reduced 
 
341 bioavailability on the beneficial effects of polyphenols supplied through the PR- 
 
342 diet, linear correlations were computed between urinary metabolite 
 
343 concentrations and serum zonulin levels. For the LSZ sub-group, two 
 
344 conjugated phenolic acids were strongly and negatively correlated with zonulin 
 
345 levels, namely 3,4-dihydroxybenzoic acid 3-glucuronide (r = -0.47, FDR- 
 
346 corrected p = 0.042) and m-coumaric acid glucuronide (r = -0.50, FDR- 
 
347 corrected p = 0.061), but no significant associations were found with parent 
 






349 correlations were observed between zonulin and food-derived metabolites when 
 
350 considering the HSZ group (FDR-corrected p > 0.2, Table S4). Phenolic acids 
 
351 are common microbial metabolites derived from the intestinal degradation of 
 
352 multiple polyphenol classes, although they can also be present in original 
 
353 foods.18 Thus, these results reinforce that the gut microbiota is responsible to a 
 
354 large extent for the bioavailability and subsequent biological activity elicited by 
 
355 dietary polyphenols. In this context, multiple in vitro and in vivo studies have 
 
356 previously reported that polyphenols (e.g. quercetin, kaempferol, myricetin, 
 
357 genistein, catechin, curcumin) can modulate the intestinal barrier function by 
 
358 promoting TJ integrity, protecting against inflammatory and oxidative 
 
359 disruptions, and consequently decreasing intestinal permeability.16 However, 
 
360 the results presented here allows hypothesizing that (i) microbial phenolic acids 
 
361 could be the major contributors to the IP improvement induced by the PR- 
 
362 dietary intervention in older subjects, and (ii) that the efficacy of dietary 
 
363 polyphenols is considerably impaired in subjects with increased IP dysfunction. 
 
364 In conclusion, we have demonstrated in the present study a connection 
 
365 between the degree of IP at baseline and the bioavailability of dietary 
 
366 polyphenols in older adults. On the basis of our findings and previous literature, 
 
367 we hypothesize that disturbances in the gut microbiota composition and IP- 
 
368 associated regulation of the phase II methylation of polyphenols could explain, 
 
369 at least in part, the metabolomics results presented here. Furthermore, we also 
 
370 found that microbial metabolites could be the major contributors to the biological 
 
371 activity elicited by dietary polyphenols, being this bioactivity significantly 
 
372 impaired in older subjects with increased IP. To validate these hypotheses, 
 






374 changes in the IP (i.e. serum zonulin) and the food metabolome with the gut 
 
375 microbiota composition. Therefore, this work highlights the crucial need of 
 
376 developing personalized nutritional strategies for managing the IP in older 
 
377 adults, and the pivotal role of gut microbiota in modulating the beneficial effects 
 




380 Abbreviations. C, control; HSZ, higher serum zonulin at baseline; IP, intestinal 
 
381 permeability; LSZ, lower serum zonulin at baseline; PR, polyphenol-rich;TJ, 
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Table 1. Urinary Food and Microbiota-related Metabolites Significantly Altered after the PR-diet for the Entire MaPLE Population, 
the LSZ and HSZ Sub-groups. Results are Expressed as the Percentage of Change, with FDR-corrected p-values in Brackets (NS, 
Non-Significant). 
metabolite MaPLE (N=51) LSZ (N=26) HSZ (N=25) 
phenolic acids, hydroxybenzenes & hydroxybenzaldehydes (microbiota) 
2-hydoxybenzoic acid glucuronide 186.7 (3.3·10-2) 317.5 (1.1·10-2) 44.4 (NS) 
3-hydoxybenzoic acid glucuronide 208.5 (1.8·10-3) 87.6 (1.1·10-2) 81.7 (NS) 
4-hydoxybenzoic acid glucuronide 85.1 (4.5·10-2) 92.9 (NS) 76.1 (NS) 
3-hydoxybenzoic acid sulfate 634.9 (1.1·10-4) 332.6 (8.4·10-3) 454.4 (NS) 
3,4-dihydoxybenzoic acid 3-glucuronide 217.6 (2.3·10-4) 329.9 (9.1·10-3) 95.0 (NS) 
3,4-dihydoxybenzoic acid 4-glucuronide 99.0 (2.3·10-4) 118.1 (2.0·10-2) 74.8 (3.2·10-2) 
3,4-dihydoxybenzoic acid 3-sulfate 134.0 (4.3·10-2) 156.0 (NS) 111.0 (NS) 
hippuric acid 864.6 (3.7·10-2) 1062.3 (NS) 658.8 (NS) 
3-hydroxyhippuric acid 1715.4 (4.3·10-2) 1009.7 (NS) 2450.5 (NS) 







isovanillic acid glucuronide 193.9 (2.0·10-3) 281.9 (2.3·10-2) 94.0 (NS) 
syringic acid 155.1 (2.2·10-3) 104.5 (1.0·10-2) 61.7 (NS) 
4-methylgallic acid 548.8 (2.6·10-2) 824.4 (1.4·10-2) 287.1 (NS) 
methylgallic acid glucuronide 75.3 (5.5·10-4) 85.6 (1.8·10-2) 64.5 (NS) 
methylgallic acid sulfate 235.3 (2.5·10-2) 248.9 (NS) 221.1 (NS) 
3-hydoxyphenylacetic acid 187.3 (2.3·10-4) 150.7 (4.0·10-3) 185.7 (NS) 
4-hydoxyphenylacetic acid glucuronide 91.6 (4.1·10-2) 77.4 (NS) 78.2 (NS) 
3,4-dihydoxyphenylacetic acid glucuronide 870.3 (1.8·10-3) 107.3 (1.1·10-2) 56.9 (NS) 
homovanillic acid glucuronide 200.2 (1.9·10-2) 263.3 (NS) 131.6 (NS) 
homovanillyl alcohol 104.5 (1.7·10-2) 65.8 (NS) 77.9 (NS) 
o-coumaric acid 133.6 (9.9·10-4) 215.2 (1.3·10-2) 76.4 (NS) 
o-coumaric acid glucuronide 158.9 (NS) 223.6 (4.5·10-2) 88.3 (NS) 
m-coumaric acid glucuronide 222.5 (1.2·10-5) 292.3 (2.8·10-3) 169.3 (2.4·10-2) 
p-coumaric acid glucuronide 224.9 (1.2·10-3) 303.3 (4.7·10-2) 143.2 (3.2·10-2) 







caffeic acid 3-glucuronide 84.4 (2.2·10-3) 118.9 (2.4·10-2) 48.5 (3.2·10-2) 
caffeic acid 4-glucuronide 167.4 (7.3·10-4) 206.8 (NS) 126.3 (2.2·10-2) 
ferulic acid glucuronide 582.2 (2.1·10-3) 57.5 (NS) 100.2 (3.2·10-2) 
isoferulic acid glucuronide 1158.7 (9.4·10-3) 168.5 (NS) 80.9 (NS) 
ferulic acid sulfate 44.9 (4.8·10-2) 55.3 (NS) 34.0 (NS) 
isoferulic acid sulfate 109.1 (3.6·10-2) 157.1 (NS) 57.0 (NS) 
methylpyrogallol sulfate 312.0 (2.6·10-3) 492.4 (1.8·10-2) 124.1 (NS) 
4-methylcatechol glucuronide (isomer 1) 166.7 (1.3·10-3) 190.1 (1.7·10-3) 141.0 (NS) 
4-methylcatechol glucuronide (isomer 2) 333.5 (3.8·10-2) 495.2 (3.5·10-2) 157.1 (NS) 
vanillin 119.0 (3.3·10-2) 183.8 (3.3·10-2) 51.4 (NS) 
flavan-3-ols 
(epi)catechin glucuronide (isomer 1) 169.7 (1.2·10-4) 281.4 (7.6·10-3) 72.9 (NS) 
(epi)catechin glucuronide (isomer 2) 433.2 (1.9·10-5) 602.2 (6.1·10-3) 348.7 (1.1·10-2) 
(epi)catechin glucuronide (isomer 3) 679.6 (5.5·10-4) 1053.2 (2.1·10-2) 341.6 (NS) 







(epi)catechin sulfate (isomer 1) 1678.6 (2.0·10-2) 3790.6 (3.2·10-2) 1150.9 (NS) 
(epi)catechin sulfate (isomer 2) 4687.8 (5.5·10-3) 5271.0 (1.7·10-2) 2157.8 (NS) 
methyl(epi)catechin glucuronide (isomer 1) 294.7 (1.3·10-3) 324.1 (NS) 181.4 (NS) 
methyl(epi)catechin glucuronide (isomer 2) 334.7 (2.0·10-3) 428.9 (NS) 168.6 (NS) 
methyl(epi)catechin glucuronide (isomer 3) 1034.0 (2.6·10-8) 1232.1 (3.5·10-4) 813.9 (2.7·10-3) 
methyl(epi)catechin glucuronide (isomer 4) 391.6 (8.1·10-8) 556.0 (6.5·10-4) 207.7 (2.7·10-3) 
methyl(epi)catechin sulfate (isomer 1) 711.0 (2.5·10-3) 700.6 (NS) 721.8 (NS) 
methyl(epi)catechin sulfate (isomer 2) 1194.0 (1.9·10-5) 725.3 (1.9·10-2) 1662.6 (6.4·10-3) 
methyl(epi)catechin sulfate (isomer 3) 4601.4 (1.2·10-6) 1833.2 (8.9·10-4) 7485.0 (4.6·10-3) 
methyl(epi)catechin sulfate (isomer 4) 1619.9 (3.5·10-8) 1291.8 (1.3·10-4) 1962.2 (4.6·10-3) 
methyl(epi)catechin sulfate (isomer 5) 2701.9 (6.0·10-6) 1964.3 (2.3·10-3) 3471.5 (1.1·10-2) 
methyl(epi)catechin sulfate (isomer 6) 817.5 (1.2·10-6) 861.1 (1.6·10-3) 767.7 (4.4·10-3) 
hydroxyphenyl-γ-valeric acids & hydroxyphenyl-γ-valerolactones (microbiota) 
5-(3’,4’-dihydroxyphenyl)-4-hydroxyvaleric acid 3’-glucuronide 367.7 (9.5·10-4) 681.5 (2.3·10-2) 116.6 (NS) 







5-(3’,4’-dihydroxyphenyl)-4-hydroxyvaleric acid 3’-sulfate 2579.2 (7.9·10-4) 4018.7 (2.8·10-2) 1079.7 (NS) 
5-(3’,4’-dihydroxyphenyl)-γ-valerolactone 3’-glucuronide 6782.4 (1.2·10-5) 10020.4 (3.1·10-3) 3544.4 (3.2·10-2) 
5-(3’,4’-dihydroxyphenyl)-γ-valerolactone 4’-glucuronide 1415.3 (1.0·10-4) 2534.3 (4.8·10-3) 245.4 (NS) 
5-(3’,4’-dihydroxyphenyl)-γ-valerolactone 3’-sulfate 948.5 (4.1·10-5) 605.6 (4.2·10-3) 195.6 (NS) 
5-(3’,4’-dihydroxyphenyl)-γ-valerolactone 4’-sulfate 7772.8 (1.2·10-3) 13594.6 (3.5·10-2) 1673.8 (NS) 
5-(3’,4’,5’-trihydroxyphenyl)-γ-valerolactone 3’-sulfate 2393.4 (7.6·10-4) 331.6 (8.9·10-4) 320.6 (NS) 
5-(3’,4’,5’-trihydroxyphenyl)-γ-valerolactone 4’-sulfate 12184.4 (2.0·10-2) 22850.4 (NS) 548.7 (NS) 
5-(4’-hydroxy-3’-methoxyphenyl)-γ-valerolactone 377.3 (9.3·10-3) 507.2 (3.2·10-2) 247.5 (NS) 
5-(4’-hydroxy-3’-methoxyphenyl)-γ-valerolactone glucuronide 4957.0 (7.2·10-5) 7987.1 (4.5·10-3) 1800.6 (NS) 
5-(4’-hydroxy-3’-methoxyphenyl)-γ-valerolactone sulfate 1342.5 (1.1·10-4) 2065.2 (4.5·10-3) 589.8 (NS) 
Urolithins (microbiota) 
urolithin A glucuronide 23040.5 (7.6·10-4) 38347.0 (3.5·10-4) 10649.5 (NS) 
urolithin A sulfate 998.1 (8.2·10-4) 1397.2 (1.3·10-3) 660.4 (NS) 
Enterolignans (microbiota) 








cyanidin 3-glucoside 523.6 (8.5·10-4) 649.3 (1.0·10-2) 421.4 (NS) 
xanthine alkaloids 
theobromine 2138.1 (3.2·10-3) 3983.6 (2.1·10-2) 215.7 (NS) 
other flavonoids 
naringenin glucuronide 520.7 (NS) 804.3 (2.6·10-2) 237.1 (NS) 
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